Research programme: NEK7 targetting anti-inflammatories - Monte Rosa Therapeutics
Latest Information Update: 04 Apr 2022
At a glance
- Originator Monte Rosa Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action NLRP3 protein inhibitors; Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Inflammation
Most Recent Events
- 01 Apr 2022 Pharmacodynamics data from research studies in Inflammation released by Monte Rosa Therapeutics
- 25 Aug 2021 NEK7 targetting anti-inflammatories are available for licensing as of 25 Aug 2021. https://ir.monterosatx.com/
- 12 Aug 2021 Early research in Inflammation in USA (unspecified route)